Our observation that decreasing DRP-1 levels can have detrimental effects in a body wall muscle model of HD, suggests that DRP1 may not be an ideal therapeutic target for HD, or that great care must be taken to ensure that DRP1 levels are only decreased by a certain amount. Here, DNM1L is linked to Huntington disease.